Trial Profile

Phase I Clinical Trial Assessing the Combination of Chemokine Modulation With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 28 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Celecoxib (Primary) ; Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Interferon alpha-2b (Primary) ; Paclitaxel (Primary) ; Rintatolimod (Primary)
Indications Advanced breast cancer; Early breast cancer; Male breast cancer; Triple negative breast cancer
Focus Adverse reactions

Most Recent Events

11 Sep 2023 Results published in the ClinicalTrials.gov Trial Registry
11 Sep 2023 Results published in the AIM ImmunoTech Media Release
12 Jun 2023 According to a AIM ImmunoTech media release, currently data analysis is ongoing and full study results publication are expected before the end of the year.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com